Product Description
Inhibikase is developing IKT148X, a small molecule c-Abl for the treatment of Multiple System Atrophy & Dementia with Lewy Body. (Sourced from: https://www.inhibikase.com/pipeline)
Mechanisms of Action: CABL Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inhibikase Therapeutics
Company Location: Eastern America
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Lewy Body Dementia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|